Taimei Technology and C&R Research partner to build AI clinical trial platform in South Korea

Taimei Technology and South Korea's C&R Research will co-develop an AI system for clinical trial data management and workflow automation. The platform auto-generates case report forms and test cases, cutting manual work for development and QA teams.

Categorized in: AI News IT and Development
Published on: May 08, 2026
Taimei Technology and C&R Research partner to build AI clinical trial platform in South Korea

Taimei Technology and C&R Research Partner on AI Clinical Trial Platform

Taimei Technology and South Korea's C&R Research signed a strategic partnership to co-develop an AI-powered system for managing clinical trial operations. C&R Research will deploy Taimei's digital platforms across several trial projects, automating key workflows in trial design and data management.

The partnership centers on Taimei's electronic data capture (EDC) plus intelligent data management (iDM) Agent. The system handles intelligent data capture, automated electronic case report form creation, and test case development-tasks that typically consume significant developer and QA resources.

C&R Research CEO Moon Tae Yoon said the collaboration addresses growing complexity in clinical trials. "AI-based data management and operational automation are emerging as essential competitive factors," he said.

Taimei's approach uses what the company calls an AI Agent matrix designed for different stages of the clinical research lifecycle. The platform integrates with South Korea's existing trial infrastructure rather than replacing it.

Taimei chairman Zhao Lu framed the deal as an opportunity to apply experience from global markets to the South Korean market. "We look forward to collaborating with more Korean ecosystem partners to continuously drive the intelligent transformation of clinical trials," he said.

For IT and development teams, the partnership signals where clinical trial software is heading. Rather than manually building eCRFs and test cases, teams will configure AI agents to generate them based on trial parameters. Data governance and capture workflows become codified in the platform rather than managed through spreadsheets and custom scripts.

South Korea hosts an established drug development ecosystem with active participation in international trial pipelines, making it a strategic market for this type of platform. Industry analysts expect the partnership to accelerate adoption of AI-driven tools across the country's clinical research operations.

Learn more about AI Agents & Automation and how they apply to AI for IT & Development roles.


Get Daily AI News

Your membership also unlocks:

700+ AI Courses
700+ Certifications
Personalized AI Learning Plan
6500+ AI Tools (no Ads)
Daily AI News by job industry (no Ads)